11.13.20
6 min. Read

Scoop: Amwell in talks to buy Omada

Issue 078

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last Friday I wrote about ICER's blistering report on Pear, Orexo's DTC move with its substance use disorder DTx, plus feedback for CMS on its plans for reimbursing breakthrough devices.

And if you

Sign-up for the newsletter for access.

It's a good one, too.

This article is for Exits & Outcomes subscribers only. Subscribe now to get the weekly newsletter. Enter your email below to subscribe today!

×

Newsletters

Filter by
All Selling to Employers Prescription Digital Therapeutics National Virtual Clinics
    430 articles
  • First
  • Previous
    • 1 of 43
  • Next
  • Last
Flo Health’s 2025 revenue, expenses, losses and more.
7.31.26
4 min. Read
Samsung’s ACCESS Model partner. More ACCESS dropouts. Trials.
7.24.26
6 min. Read
CMS proposes to gut RPM/RTM. Thyme revenue. Swing Therapeutics acquired.
7.15.26
6 min. Read
Clinical trials snapshot: OpenEvidence, Hinge, Oura, North Shore Therapeutics, and more
7.10.26
9 min. Read
Hello Heart, Form Health pricing. Headway off the ACCESS Model list
6.26.26
3 min. Read
Oura subscription revs, rings sold, hardware margin. New ACCESS Model participants
6.05.26
7 min. Read
Six years of Oura’s financials: Revenue, profits, marketing spend and more
5.22.26
4 min. Read
ACCESS Model’s first dropout? Plus: A few new participants
5.08.26
6 min. Read
Are these Utah’s next four AI experiments? Plus: More on the Utah Pharmacy Board’s questions about Doctronic
4.17.26
9 min. Read
Emails show how Doctronic’s AI pilot blindsided Utah’s Medical Board
4.10.26
13 min. Read
  • First
  • Previous
    • 1 of 43
  • Next
  • Last